{"id":146535,"date":"2026-04-20T15:51:33","date_gmt":"2026-04-20T19:51:33","guid":{"rendered":"https:\/\/medcitynews.com\/?p=146535"},"modified":"2026-04-21T03:11:29","modified_gmt":"2026-04-21T07:11:29","slug":"eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/","title":{"rendered":"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition"},"content":{"rendered":"<p>Eli Lilly is expanding its reach in genetic medicines with a multi-billion dollar deal to <a href=\"https:\/\/www.prnewswire.com\/news-releases\/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies-302747122.html\" target=\"_blank\" rel=\"noopener\">acquire Kelonia Therapeutics<\/a>, a startup whose most advanced drug candidate is a cell therapy in development for multiple myeloma. Beyond the safety and manufacturing advantages Kelonia\u2019s in vivo approach brings to this type of blood cancer, the biotech comes with a platform technology that could help Lilly make genetic medicines more accessible to patients as treatments for additional cancers and other diseases.<\/p>\n<p>According to financial terms announced Monday, Lilly is paying $3.25 billion up front for Kelonia. Shareholders of the Boston-based startup could receive up to $3.75 billion more if Kelonia\u2019s assets achieve milestones.<\/p>\n<p>Cell therapies are made by engineering a T cell to express a receptor that targets a cancer cell. For the currently available treatments in this class of so-called CAR T therapies, the engineering steps happen in a lab. Beyond the cost and complexity associated with this ex vivo manufacturing, patient preparation to receive a cell therapy includes a preconditioning drug regimen that introduces additional toxicity and complication risks.<\/p>\n<p>For Kelonia\u2019s therapies, engineering of cells happens inside the patient. This in vivo approach avoids the complexity and costs associated with currently available cell therapies and does not require a preconditioning regimen. The startup\u2019s drugs come from a proprietary technology platform that uses lentivirus-based particles engineered to enter T cells inside the patient, getting them to express the chimeric antigen receptor (CAR) that makes a CAR T therapy.<\/p>\n<p>Kelonia spun out of the Massachusetts Institute of Technology. In a 2022 interview, then Chief Scientific Officer Kevin Friedman said <a href=\"https:\/\/medcitynews.com\/2022\/05\/car-t-without-the-toxicity-kelonia-gets-50m-for-a-new-take-on-cell-therapy\/\" target=\"_blank\" rel=\"noopener\">Kelonia\u2019s technology modifies the envelope of a lentivirus to \u201cdetarget\u201d it<\/a> from binding to unintended targets. Kelonia then decorates the lentivirus with antibodies that direct the virus and its genetic payload to the proper destination in the body. These therapies are intended to be one-time treatments. When Kelonia emerged from stealth, Friedman said the startup\u2019s first indication would be a blood cancer. But he added that other indications could be addressed by engineering the lentivirus to go after a different tissue and switching out the genetic cargo. Friedman has since become Kelonia\u2019s CEO.<\/p>\n<p>Even before the Lilly acquisition announcement, Kelonia\u2019s technology had already caught the eye of pharmaceutical companies. In 2024, <a href=\"https:\/\/medcitynews.com\/2024\/02\/astellas-pharma-in-vivo-cell-therapy-cancer-kelonia-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Astellas Pharma began a collaboration with the startup<\/a> to discover and develop in vivo CAR T therapies for targets that were not disclosed. Targets are also undisclosed for a <a href=\"https:\/\/jnjinnovation.com\/news\/strategic-partners-in-the-news\/kelonia-therapeutics-enters-into-strategic-collaboration-with-johnson--johnson-to-advance-in-vivo-cart-therapies\" target=\"_blank\" rel=\"noopener\">Johnson &amp; Johnson collaboration<\/a> that started last fall.<\/p>\n<p>Lead Kelonia therapeutic candidate KLN-1010 is designed to target BCMA, a protein expressed on the surface of the B cells that drive multiple myeloma. BCMA is already targeted by <a href=\"https:\/\/medcitynews.com\/2021\/03\/bristol-myers-squibb-wins-first-car-t-therapy-approval-in-multiple-myeloma\/\" target=\"_blank\" rel=\"noopener\">Abecma, from Bristol Myers Squibb<\/a>, and <a href=\"https:\/\/medcitynews.com\/2022\/03\/jj-legend-win-fda-nod-for-cell-therapy-challenger-to-bms-in-multiple-myeloma\/\" target=\"_blank\" rel=\"noopener\">Carvykti, from partners Johnson &amp; Johnson and Legend Biotech<\/a>. Both are ex vivo cell therapies that come with the manufacturing challenges and complication risks associated with the broader CAR T drug class.<\/p>\n<p>The first human data for KLN-1010 were presented last December during the annual meeting of the American Society of Hematology. In all <a href=\"https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%202\/LBA-1\/556929\/Minimal-residual-disease-MRD-negative-outcomes\" target=\"_blank\" rel=\"noopener\">three patients treated with a high dose<\/a> and a fourth who received a lower dose, results showed <a href=\"https:\/\/www.businesswire.com\/news\/home\/20251209935959\/en\/Kelonia-Therapeutics-Presents-First-in-Human-Data-From-Phase-1-inMMyCAR-Study-of-KLN-1010-in-vivo-BCMA-CAR-T-Therapy-at-the-American-Society-of-Hematology-ASH-2025-Annual-Meeting\" target=\"_blank\" rel=\"noopener\">100% minimal residual disease-negative response rate<\/a>, meaning there were no detectable cancer cells. An excessive immune response called cytokine release syndrome is a known complication risk for CAR T therapy. No incidents of this complication were classified at Grade 3 or higher. Results also showed no neurotoxicity and lower rates of cytopenias, the low levels of blood cells that is another known risk of CAR T treatment. In the acquisition announcement, Jacob Van Naarden, executive vice president and president of Lilly Oncology and head of corporate business development, pointed to the potential manufacturing and safety advantages of Kelonia\u2019s technology.<\/p>\n<p>\u201cThe early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia&#8217;s platform&#8221;, he said. \u201cWe look forward to working together with the Kelonia team to rapidly advance KLN-1010 to address patient need and recognize the full potential of their platform in other conditions where patients may benefit.&#8221;<\/p>\n<p>Kelonia is Lilly\u2019s second acquisition of an in vivo cell therapy startup this year. In February, the pharma giant struck a deal to <a href=\"https:\/\/medcitynews.com\/2026\/02\/eli-lilly-orna-acquisition-in-vivo-car-t-cell-therapy-autoimmune-disease-immunology-lly\/\" target=\"_blank\" rel=\"noopener\">buy Orna Therapeutics, whose lead program is an in vivo CAR T treatment<\/a> designed to target the protein CD19 on the surface of disease-driving B cells. This Orna program is on track to begin Phase 1 testing in autoimmune diseases.<\/p>\n<p>Lilly expects to close the Kelonia acquisition in the second half of this year. It follows <a href=\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/\" target=\"_blank\" rel=\"noopener\">Lilly\u2019s buyout last week of CrossBridge Bio, a startup developing antibody drug conjugates for cancer<\/a>. Pitchbook Senior Biotech &amp; Pharma Analyst Ben Zercher sees the Kelonia deal as another example of Lilly building out its pipeline by deploying cash from the blockbuster sales of its metabolic drugs Mounjaro and Zepbound. In an email, Zercher said the Orna and Kelonia acquisitions are complementary. While Orna uses circular RNA to address autoimmune diseases, Kelonia\u2019s viral vector technology is built for the durable effects needed in cancers like multiple myeloma.<\/p>\n<p>\u201cThe $3.25 billion upfront for a Phase 1 program may look rich, but it reflects the scarcity of clinical-stage in vivo CAR T assets,\u201d Zercher said. \u201cIf the modality delivers on its promise, it could dramatically expand patient access by eliminating the manufacturing and treatment burden of today\u2019s ex vivo therapies. With new entrants likely to pressure GLP-1 pricing in the obesity space, Lilly is using today\u2019s cash flow to fund tomorrow\u2019s growth drivers.\u201d<\/p>\n<p>Kelonia is actually Lilly\u2019s third in vivo genetic medicines acquisition in the past year. Last summer, the pharma company agreed to pay $1 billion to buy Verve Therapeutics, developer of in vivo gene-editing medicines for cardiovascular diseases. Lead program VERVE-102 is designed to edit the PCSK9 gene, which provides instructions for making a protein that regulates cholesterol levels. This program is currently in early-stage clinical development.<\/p>\n<p><em>Illustration: Ruslanas Baranauskas\/Science Photo Library, via Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly\u2019s  acquisitions of Verve Therapeutics and Orna Therapeutics in the past year, each taking different approaches to developing in vivo genetic medicines. <\/p>\n","protected":false},"author":25932,"featured_media":140372,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,54,60],"tags":[14217,29460,46027,2196,47737,23562,8559],"class_list":["post-146535","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-pharma-channel","category-startup-channel","tag-cancer","tag-cell-therapy","tag-deals","tag-eli-lilly","tag-kelonia-therapeutics","tag-multiple-myeloma","tag-startup"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly\u2019s acquisitions of Verve Therapeutics and Orna Therapeutics in the past year, each taking different approaches to developing in vivo genetic medicines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T19:51:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T07:11:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"803\" \/>\n\t<meta property=\"og:image:height\" content=\"435\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition\",\"datePublished\":\"2026-04-20T19:51:33+00:00\",\"dateModified\":\"2026-04-21T07:11:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/\"},\"wordCount\":1016,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg\",\"keywords\":[\"cancer\",\"cell therapy\",\"Deals\",\"Eli Lilly\",\"Kelonia Therapeutics\",\"multiple myeloma\",\"startup\"],\"articleSection\":[\"BioPharma\",\"Pharma\",\"Startups\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/\",\"url\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/\",\"name\":\"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg\",\"datePublished\":\"2026-04-20T19:51:33+00:00\",\"dateModified\":\"2026-04-21T07:11:29+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg\",\"width\":803,\"height\":435},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition - MedCity News","og_description":"Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly\u2019s acquisitions of Verve Therapeutics and Orna Therapeutics in the past year, each taking different approaches to developing in vivo genetic medicines.","og_url":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/","og_site_name":"MedCity News","article_published_time":"2026-04-20T19:51:33+00:00","article_modified_time":"2026-04-21T07:11:29+00:00","og_image":[{"width":803,"height":435,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition","datePublished":"2026-04-20T19:51:33+00:00","dateModified":"2026-04-21T07:11:29+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/"},"wordCount":1016,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg","keywords":["cancer","cell therapy","Deals","Eli Lilly","Kelonia Therapeutics","multiple myeloma","startup"],"articleSection":["BioPharma","Pharma","Startups"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/","url":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/","name":"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg","datePublished":"2026-04-20T19:51:33+00:00","dateModified":"2026-04-21T07:11:29+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg","width":803,"height":435},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=146535"}],"version-history":[{"count":3,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146535\/revisions"}],"predecessor-version":[{"id":146560,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146535\/revisions\/146560"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/140372"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=146535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=146535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=146535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}